glp 1 no consultation What is the future of GLP-1 trends: PwC Are YOU a Slow/Non-Responder to

Liraglutide (Victoza), injectable semaglutide (Ozempic), and dulaglutide (Trulicity) have demonstrated statistically significant reductions in major adverse cardiovascular events in clinical trials

However, it is important to note that samples may have to be produced for submission of product registration

Providers should explain that these side effects are most likely to occur in the first few weeks and usually improve as the body adjusts

12 There are currently 54 active clinical trials studying the expanded use of GLP-1s in other illnesses beyond diabetes and obesity, with the first such launch expected in 2025